10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||||||||||||
| |||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
REGENERON PHARMACEUTICALS, INC. | |||
Ticker: REGN Fiscal Year: 2019 | |||
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME | |||
Period Ending Dec 31, 2019 10-K (Filed: Feb 7, 2020) | |||
| (In Thousands) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | |
| Statements of Operations | |||
| Revenues: | |||
| Revenues | $ 7,863,400 | 6,710,800 | 5,872,200 |
| Expenses: | |||
| Research and development | 3,036,600 | 2,186,100 | 2,075,100 |
| Selling, general, and administrative | 1,834,800 | 1,556,200 | 1,320,400 |
| Total expenses | 5,653,600 | 4,176,400 | 3,792,600 |
| Income from operations | 2,209,800 | 2,534,400 | 2,079,600 |
| Other income (expense): | |||
| Other income (expense), net | 249,500 | 47,300 | 24,000 |
| Interest expense | (30,200) | (28,200) | (25,100) |
| Total other income (expense) | 219,300 | 19,100 | (1,100) |
| Income before income taxes | 2,429,100 | 2,553,500 | 2,078,500 |
| Income tax expense | (313,300) | (109,100) | (880,000) |
| Net income | 2,115,800 | 2,444,400 | 1,198,500 |
| Net income per share - basic (in dollars per share) | 19.38 | 22.65 | 11.27 |
| Net income per share - diluted (in dollars per share) | 18.46 | 21.29 | 10.34 |
| Weighted average shares outstanding - basic (in shares) | 109,200 | 107,900 | 106,300 |
| Weighted average shares outstanding - diluted (in shares) | 114,600 | 114,800 | 115,900 |
| Statements of Comprehensive Income | |||
| Net income | 2,115,800 | 2,444,400 | 1,198,500 |
| Other comprehensive income (loss), net of tax: | |||
| Unrealized gain (loss) on marketable securities | 35,900 | (7,000) | 12,700 |
| Unrealized (loss) gain on cash flow hedges | (2,500) | ||
| Unrealized (loss) gain on cash flow hedges | 700 | 800 | |
| Comprehensive income | 2,149,200 | 2,438,100 | 1,212,000 |
| Project | |||
| Sanofi | |||
| Product and Service | |||
| Product and service, other | |||
| Revenues | 1,426,800 | 1,111,100 | 877,200 |
| Bayer | |||
| Revenues | 1,188,800 | 1,076,700 | 938,100 |
| Other | |||
| Revenues | 413,400 | 416,800 | 338,400 |
| Product and Service | |||
| Product | |||
| Revenues | 4,834,400 | 4,106,200 | 3,718,500 |
| Cost of goods sold | 362,300 | 180,000 | 202,500 |
| Collaboration and contract manufacturing | |||
| Cost of goods sold | 419,900 | 254,100 | 194,600 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
REGENERON PHARMACEUTICALS, INC. | |||
Ticker: REGN Fiscal Year: 2019 | |||
CONSOLIDATED STATEMENTS OF CASH FLOWS | |||
Period Ending Dec 31, 2019 10-K (Filed: Feb 7, 2020) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | |
| Cash flows from operating activities: | |||
| Net income | $ 2,115,800 | 2,444,400 | 1,198,500 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation and amortization | 210,300 | 148,200 | 145,500 |
| Non-cash compensation expense | 464,300 | 427,400 | 507,300 |
| Other non-cash items, net | (29,300) | 12,100 | 63,500 |
| Deferred taxes | (130,600) | (140,000) | 318,800 |
| Changes in assets and liabilities: | |||
| Increase in Sanofi, Bayer, and trade accounts receivable | (473,100) | (268,900) | (362,700) |
| Increase in inventories | (335,500) | (387,900) | (314,200) |
| Increase in prepaid expenses and other assets | (130,400) | (55,700) | (113,300) |
| Increase (decrease) in deferred revenue | 294,000 | (194,500) | (113,100) |
| Increase (decrease) in accounts payable, accrued expenses, and other liabilities | 444,500 | 210,000 | (23,200) |
| Total adjustments | 314,200 | (249,300) | 108,600 |
| Net cash provided by operating activities | 2,430,000 | 2,195,100 | 1,307,100 |
| Cash flows from investing activities: | |||
| Purchases of marketable and other securities | (3,202,400) | (1,845,500) | (1,277,200) |
| Sales or maturities of marketable securities | 1,604,200 | 775,600 | 544,600 |
| Capital expenditures | (429,600) | (383,100) | (272,600) |
| Other | 0 | (10,000) | 0 |
| Net cash used in investing activities | (2,027,800) | (1,463,000) | (1,005,200) |
| Cash flows from financing activities: | |||
| Proceeds in connection with finance lease liabilities | 0 | 57,000 | |
| Payments in connection with finance lease liabilities | 0 | (19,900) | |
| Proceeds from issuance of Common Stock | 211,800 | 114,500 | 240,200 |
| Payments in connection with Common Stock tendered for employee tax obligations | (188,000) | (187,200) | (301,700) |
| Repurchases of Common Stock | (275,900) | (4,400) | 0 |
| Net cash used in financing activities | (252,100) | (77,100) | (24,400) |
| Net increase in cash, cash equivalents, and restricted cash | 150,100 | 655,000 | 277,500 |
| Cash, cash equivalents, and restricted cash at beginning of period | 1,480,200 | 825,200 | |
| Cash, cash equivalents, and restricted cash at end of period | 1,630,300 | 1,480,200 | 825,200 |
| Supplemental disclosure of cash flow information | |||
| Cash paid for interest (net of amounts capitalized) | 25,000 | 22,300 | 18,700 |
| Cash paid for income taxes | 342,300 | 205,600 | 754,800 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
REGENERON PHARMACEUTICALS, INC. | ||
Ticker: REGN Fiscal Year: 2019 | ||
CONSOLIDATED BALANCE SHEETS | ||
Period Ending Dec 31, 2019 10-K (Filed: Feb 7, 2020) | ||
| (In Thousands, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2019 | Dec 31, 2018 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $ 1,617,800 | 1,467,700 |
| Marketable securities | 1,596,500 | 1,342,200 |
| Accounts receivable - trade, net | 2,100,000 | 1,723,700 |
| Accounts receivable from Sanofi | 260,600 | 226,400 |
| Accounts receivable from Bayer | 311,600 | 293,100 |
| Inventories | 1,415,500 | 1,151,200 |
| Prepaid expenses and other current assets | 387,100 | 243,300 |
| Total current assets | 7,689,100 | 6,447,600 |
| Marketable securities | 3,256,800 | 1,755,000 |
| Property, plant, and equipment, net | 2,890,400 | |
| Property, plant, and equipment, net | 2,575,800 | |
| Deferred tax assets | 824,200 | 828,700 |
| Other noncurrent assets | 144,700 | 127,400 |
| Total assets | 14,805,200 | 11,734,500 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable | 418,100 | 218,200 |
| Accrued expenses and other current liabilities | 1,086,800 | 772,100 |
| Deferred revenue, current | 591,700 | 452,500 |
| Total current liabilities | 2,096,600 | 1,442,800 |
| Finance lease liabilities | 713,900 | |
| Finance lease liabilities | 708,500 | |
| Deferred revenue, noncurrent | 619,000 | 464,200 |
| Other noncurrent liabilities | 286,000 | 361,700 |
| Total liabilities | 3,715,500 | 2,977,200 |
| Commitments and contingencies | ||
| Stockholders' equity: | ||
| Preferred Stock, $.01 par value; 30,000,000 shares authorized; issued and outstanding - none | 0 | 0 |
| Additional paid-in capital | 4,428,600 | 3,911,600 |
| Retained earnings | 7,379,800 | 5,254,300 |
| Accumulated other comprehensive income (loss) | 21,100 | (12,300) |
| Treasury Stock, at cost; 4,860,123 shares in 2019 and 3,990,021 shares in 2018 | (739,900) | (396,400) |
| Total stockholders' equity | 11,089,700 | 8,757,300 |
| Total liabilities and stockholders' equity | 14,805,200 | 11,734,500 |
| Project | ||
| Sanofi | ||
| Deferred revenue, current | 395,500 | 246,700 |
| Deferred revenue, noncurrent | 509,700 | 279,300 |
| Other | ||
| Deferred revenue, current | 196,200 | 205,800 |
| Deferred revenue, noncurrent | 109,300 | 184,900 |
| Class of Stock | ||
| Class A Stock | ||
| Common stock | 0 | 0 |
| Common Stock | ||
| Common stock | 100 | 100 |
| Total stockholders' equity | 100 | 100 |
| External Links | |
| REGENERON PHARMACEUTICALS, INC. (REGN) Fiscal Year 2019 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |